Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer
- 23 January 2026
- journal article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 343 (Pt 2) , 150490
Abstract
No abstract availableKeywords
Funding Information
- Fundamental Research Funds for the Central Universities (lzujbky-2023-ct06)
- National Natural Science Foundation of China (82160148)
This publication has 45 references indexed in Scilit:
- Ubiquitination in cancer: mechanisms and therapeutic opportunitiesCancer Communications, 2025
- Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer ImmunotherapyAdvanced Materials, 2025
- The mevalonate pathway in breast cancer biologyCancer Letters, 2022
- Dual proteome-scale networks reveal cell-specific remodeling of the human interactomeCell, 2021
- Palmitic acid negatively regulates tumor suppressor PTEN through T366 phosphorylation and protein degradationCancer Letters, 2020
- Links between cancer metabolism and cisplatin resistance2020
- p53 Represses the Mevalonate Pathway to Mediate Tumor SuppressionCell, 2019
- Discovery of Small Molecule WWP2 Ubiquitin Ligase InhibitorsChemistry – A European Journal, 2018
- ASPP2 suppresses invasion and TGF-β1-induced epithelial–mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancerCancer Letters, 2017
- Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activationTumor Biology, 2015